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We  describe  novel  Staphylococcal  Protein  A ligands  that enable  milder  elution  pH  for use  in afﬁnity
chromatography.  The  change  in elution  pH  is  the  result  of  point  mutations  to the  protein  sequence.  Two
novel  ligands  are  investigated  in this  study.  The  ﬁrst,  designated  Z(H18S)4,  represents  a histidine  to serine
substitution  single  mutation.  The  second,  designated  Z(H18S,  N28A)4,  is  a double  mutant  comprising  his-
tidine  to serine  and  asparagine  to  alanine  mutations.  Both  are  compared  against  the  unmutated  sequence,
designated  Z4,  which  is  currently  utilized  in  a commercially  available  Protein  A  stationary  phase  for  the
puriﬁcation  of  molecules  containing  Fc  domains.  The  ligands  are  coupled  to  a chromatography  support
matrix  and tested against  a panel  of  antibodies  and  an Fc  fusion  protein  for elution  pH,  dynamic  bind-
ing  capacity,  step-wise  elution,  and  capture  from  clariﬁed  culture  media.  Results  demonstrate  that  thefﬁnity chromatography novel  ligands  result  in milder  elution  pH,  on average  >0.5  pH  units,  when  tested  in  a pH  gradient.  For
step-wise  elution  at pH  4.0, the  Z(H18S,  N28A)4  ligand  showed  on  average  a greater  than  30%  increase
in  yield  compared  to  Z4.  Importantly,  for the  antibodies  tested  the  mutations  did  not  result  in a decrease
in  dynamic  binding  capacity  or other  desirable  attributes  such  as  selectivity.  A  potential  application  of
the novel  ligands  is  shown  with  a pH sensitive  molecule  prone  to  aggregation  under acidic  conditions.
© 2014  The  Authors.  Published  by Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY-NC-SA
license  (http://creativecommons.org/licenses/by-nc-sa/3.0/).. Introduction
Staphylococcal Protein A (SpA) is a 42 kDa single chain polypep-
ide localized to the outer surface of Staphylococcus aureus [1–4].
ative SpA comprises ﬁve highly homologous Fc binding domains
esignated E, D, A, B, and C, followed by a cell wall binding domain
esignated X [5–7]. The ﬁve Fc binding domains are organized in an
nti-parallel -helical arrangement [5]. The structure of an IgG Fc
ragment bound to SpA has been solved and the amino acid residues
mplicated in binding have been identiﬁed [3,8].
The potential of SpA to be used as an afﬁnity ligand for pro-
ein puriﬁcation has been recognized for decades. Early SpA afﬁnity
esins consisted of native Protein A coupled to a base matrix most
ften through covalent bonding to amines. Since then, dramatic
mprovements have been made in Protein A chromatography sta-
ionary phases. Among the most signiﬁcant innovations in SpA
∗ Corresponding author. Tel.: +1 301 398 4142; fax: +1 301 398 9322.
E-mail address: hunterak@medimmune.com (A.K. Hunter).
1 These authors contributed equally to this work.
ttp://dx.doi.org/10.1016/j.chroma.2014.08.046
021-9673/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unengineering is the Z domain, which represents a synthetic analogue
of the native B domain developed for puriﬁcation of Fc-fusion pro-
teins [9,10]. A derivative of the Z domain engineered for greater
alkaline stability has gained widespread use for capture of recom-
binant therapeutic proteins.
For industrial puriﬁcation of antibodies and Fc fusion proteins,
Protein A chromatography is routinely utilized as part of a plat-
form approach [7,11–19]. In most instances, the Protein A column
is placed ﬁrst in the puriﬁcation train to capture product from
clariﬁed cell culture broth [20–22]. This conﬁguration provides an
optimal balance of cost of goods for manufacturing, process sim-
ilarity for different molecules, and process robustness. However,
process models developed to predict facility capacity and cost of
goods tend to be sensitive to Protein A capture column dynamic
binding capacity (DBC) [23,24]. As a result, the last decade has seen
introduction of multiple generations of Protein A stationary phases
designed to achieve ever higher DBCs.One disadvantage of Protein A for use as an afﬁnity chromatogra-
phy ligand is that low pH conditions, typically pH 3–4, are required
for elution of bound proteins. It is generally understood that low pH
has the potential to destabilize proteins and contribute to aggregate
der the CC BY-NC-SA license (http://creativecommons.org/licenses/by-nc-sa/3.0/).
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Table 1
Stationary phase properties.
Ligand name Base matrix d¯P (m)a Normalized
ligand density
Z4 Cross-linked agarose 85 1.00
Z(H18S)4 Cross-linked agarose 85 1.05
Z(H18S, N28A)4 Cross-linked agarose 85 1.03
a Average bead diameter.
Table 2
Antibody and Fc-fusion protein properties.
Molecule Type pIa MWb (kDa) r¯c (nm)
mAb1 IgG1 9.2 147 5.7
mAb2 IgG1 8.9 146 5.3
mAb3 IgG1 9.4 145 5.4
mAb4 IgG1 8.4 144 5.6
mAb5 IgG4 7.1 147 6.6
BsAb Bispeciﬁc 8.2 200 6.5
Fc1 Fc-fusion (IgG1) 5.7 90 4.7
aT.M. Pabst et al. / J. Chrom
ormation [17,19,25]. In particular, Fc-fusion proteins are often very
ensitive to low pH conditions, greatly complicating the process
evelopment and manufacturing of these proteins. To overcome
his challenge, successful strategies have included the use of aggre-
ation suppressors such as arginine and urea [17,26], as well as SpA
ngineering to increase elution pH through destabilization of the
igand itself or the ligand–Fc interaction [27,28].
When designing a Protein A stationary phase, a balance must be
truck between several often competing properties. To minimize
ggregate formation, high elution pH is desirable; however, when
onsidering large scale bioprocessing, changes that lead to higher
lution pH must not be achieved at the expense of a substantial
eduction in DBC. Other properties associated with modern Pro-
ein A media, such as high selectivity, low elution pool volume and
igh ﬂow rates should also be maintained to the greatest extent
ossible.
In this work, we examine the chromatographic behavior of novel
 domain stationary phases engineered to achieve higher elution
H while maintaining high DBC. To study behavior under col-
mn  chromatography conditions, the ligands are expressed and
oupled to a chromatography support matrix. The effect of muta-
ions on elution pH is tested using a panel of antibodies and an
c-fusion protein under low loading conditions with a linear pH
radient. Similarly, the impact of mutations on DBC is investi-
ated with breakthrough experiments. To test performance in a
ypical bioprocess scenario, stepwise elution under high loading
onditions and product capture from clariﬁed culture broth are
nvestigated.
. Materials and methods
.1. Construction of Z domain ligands and stationary phases
Three afﬁnity ligands were used in this work, comprised of pro-
rietary Z-domain derivatives. MabSelect SuRe (GE Healthcare) is
 commercially available Protein A stationary phase that incor-
orates a ligand, designated Z4, comprising four repeats of the Z
omain engineered to be alkaline resistant. A linker with a C ter-
inal cysteine is added to the last repeat to facilitate coupling to a
hromatography support matrix. The other two  stationary phases
sed in this work incorporate novel ligands. The ﬁrst, designated
(H18S)4, is identical to the SuRe Z4 ligand with the exception of a
istidine to serine mutation at position 18 included for each repeat.
he ﬁnal stationary phase incorporates a ligand designated Z(H18S,
28A)4. It is also identical to the SuRe Z4 ligand with the excep-
ions of a histidine to serine mutation at position 18 as well as an
sparagine to alanine mutation at position 28 included for each
epeat.
The novel constructs were expressed using recombinant
scherichia coli. After fermentation, the cells were subject to heat
reatment to release the Z domain ligands into the media. The crude
xtract was then clariﬁed by microﬁltration with a 0.2 m mem-
rane. The membrane permeate was loaded onto IgG Sepharose
GE Healthcare). The resin was washed with phosphate buffered
aline (PBS) and eluted by lowering to pH 3. The elution pool was
djusted to neutral pH, reduced by addition of dithiothreitol (DTT),
nd puriﬁed by anion exchange chromatography. The puriﬁed lig-
nds were analyzed by LC–MS (Agilent) to conﬁrm the molecular
eight.
Following expression and puriﬁcation, ligands were coupled to
5 m diameter cross-linked agarose porous beads using standard
echniques via a thioether linkage. Ligand density was  determined
y amino acid analysis based on the total amino acid content recov-
red from a stationary phase sample. Table 1 summarizes the Z
omain stationary phases used in this work.pI of main peak by isoelectric focusing.
b Molecular weight by mass spectrometry, including glycosylation.
c Hydrodynamic radius measured by DLS.
2.2. Buffer reagents and protein preparations
Chemicals used for buffer preparation were obtained from
Sigma (St. Louis, MO,  USA) and JT Baker (Phillipsburg, NJ, USA).
Recombinant human serum albumin (HSA) was obtained from InVi-
tra (Fort Collins, CO, USA). Antibodies and an Fc-fusion protein were
expressed in Chinese hamster ovary (CHO) cells using standard cell
culture techniques. To generate puriﬁed material, clariﬁed cell cul-
ture broth was  puriﬁed by Protein A chromatography and then by
ion exchange chromatography. Table 2 summarizes the antibodies
and Fc-fusion proteins used in this work.
2.3. Chromatography columns and instrumentation
Chromatography experiments were conducted using a GE
Healthcare ÄKTA Explorer 100. Resins were packed to approxi-
mately 20 cm bed height in 0.5 cm diameter Tricorn columns (GE
Healthcare) for all experiments except dynamic binding capacity
experiments, which used 1.1 cm diameter Vantage L11 columns
from Millipore (Billerica, MA,  USA) packed to a 5 cm bed height.
2.4. Protein concentration determination by absorbance (A280)
Protein concentrations of puriﬁed samples were determined
using a Nanodrop 2000c from Thermo Scientiﬁc (Wilmington, DE,
USA) with the microvolume pedestal and measurement at a wave-
length of 280 nm.
2.5. Antibody concentration determination by protein A HPLC
(ProA-HPLC)
Concentration of mAbs and Fc-fusion proteins in clariﬁed cell
culture broth was determined by analytical high performance
Protein A chromatography (ProA-HPLC) using a POROS A 20
(4.6 mm i.d. × 10 cm,  20 m)  column obtained from Life Technolo-
gies (Grand Island, NY, USA) with an Agilent 1100 HPLC system
(Palo Alto, CA). The binding mobile phase buffer consisted of phos-
phate buffered saline (PBS), pH 7.2 and the elution buffer was
PBS, pH 2.2; both at a ﬂow rate of 3.5 mL/min. Each injection was
eluted for a total of 2.5 min. Samples were applied to the column
neat and the elution proﬁle was  monitored at 280 nm using the
HPLC spectrophotometer. Elution peak area was  converted to a
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rotein concentration using a standard curve generated with puri-
ed material.
.6. pH measurement
Buffer and protein solution pH was measured ofﬂine using a
evenMulti pH meter from Mettler Toledo (Columbus, OH, USA)
quipped with an InLab Expert Pro pH probe from Mettler Toledo.
he meters were calibrated with pH 2, 4, 7, and 10 standards.
.7. Dynamic binding capacity (DBC) experiments
For DBC experiments, deﬁned as 10% breakthrough, columns
ere equilibrated with 25 mM Tris, pH 7.5 and then loaded until
reakthrough was observed. Prior to column loading, puriﬁed
aterial was diluted to 1 mg/mL  with equilibration buffer to match
he equilibration conditions. All experiments were operated at a
esidence time of 4 minutes. The contributions of column void vol-
me  and system delay volume were subtracted from the protein
oad volume to obtain DBC. The maximum absorbance of the load
as measured with the column in bypass.
.8. Linear pH gradient elution chromatography
For linear pH gradient elution experiments, columns were equi-
ibrated with 25 mM Tris, 150 mM NaCl, pH 7.5 and then puriﬁed
rotein (diluted to 4 mg/mL  with equilibration buffer) was loaded
n the column to a load challenge of 5 g/L resin. The column was re-
quilibrated, washed with 25 mM citrate, pH 6.7, and then eluted
n a linear gradient to 25 mM citrate, pH 2.7 over 10 column vol-
mes. Experiments were performed at a ﬂow rate of 300 cm/h with
nline UV absorbance monitored at 280 nm.  Elution pH at the peak
aximum was calculated through linear interpolation between the
easured pH values of the two buffers used to form the gradi-
nt, taking into account column void volume and the system delay
olume.
.9. Stepwise elution chromatography
For stepwise elution experiments, columns were equilibrated
ith 25 mM  Tris, 150 mM NaCl, pH 7.5 and then puriﬁed pro-
ein (diluted to 4 mg/mL  with equilibration buffer) was loaded on
he column to a load challenge of 30 g/L resin and 10 g/L resin
or antibodies and the Fc-fusion protein, respectively. The col-
mn  was re-equilibrated and then eluted in stepwise fashion to
5 mM acetate, pH 4.0. Product pools were collected over 2 column
olumes to mimic  typical large-scale bioprocess conditions. Exper-
ments were performed at a ﬂow rate of 300 cm/hr with online UV
bsorbance monitored at 280 nm.  Step yield was determined using
ass of product in the load and pool (as determined by A280).
.10. Capture from clariﬁed cell culture broth
For capture of clariﬁed CHO cell culture broth, columns were
quilibrated with 25 mM Tris, 150 mM NaCl, pH 7.5 and then clari-
ed cell culture broth was loaded on the column to a load challenge
f 30 g/L resin and 10 g/L resin for antibodies and the Fc-fusion pro-
ein, respectively. The column was re-equilibrated and then washed
ith 25 mM Tris, 1 M NaCl, pH 7.5 to remove HCP. The column
as re-equilibrated with 25 mM Tris, 150 mM NaCl, pH 7.5 andhen eluted in stepwise fashion to 25 mM acetate, pH 4.0. Product
ools were collected over 2 column volumes. Experiments were
erformed at a ﬂow rate of 300 cm/hr with online UV absorbance
onitored at 280 nm.  Step yield was determined using mass ofFig. 1. Elution of mAb  2 in a linear pH gradient from 6.7 to 2.7 on Protein A columns
loaded to 5 g/L. The pH gradient is shown as a dotted line.
product in the load (as determined by ProA-HPLC) and pool (as
determined by A280).
2.11. High performance size exclusion chromatography (HP-SEC)
Analytical high performance size exclusion chromatography
(HP-SEC) was performed using a TSKgel G3000SWXL (7.8 mm
i.d. × 30 cm,  5 m)  column obtained from Tosoh Biosciences (King
of Prussia, PA, USA) with an Agilent 1100 HPLC system (Palo Alto,
CA). The mobile phase buffer consisted of 100 mM sodium phos-
phate, 100 mm sodium sulfate, pH 6.8 at a ﬂow rate of 1 mL/min.
Each injection was eluted for a total of 20 min. The elution proﬁle
was monitored at 280 nm using the HPLC spectrophotometer. Sam-
ples were applied to the column neat and the injection volume was
adjusted to load approximately 250 g of total protein on the col-
umn. The column was calibrated using gel ﬁltration standards from
Bio-Rad (Hercules, CA, USA).
2.12. Host cell protein measurements
Host cell protein (HCP) concentrations were measured using
the bioaffy sandwich immunoassay on the Gyrolab xP workstation
from Gyros AB (Uppsala, Sweden). Capture and detection antibod-
ies were in-house reagents raised against HCP from the cell line
used to produce the antibodies and Fc-fusion proteins used in this
work.
2.13. Residual Protein A measurements
Residual Protein A in elution pools was measured with an
in-house enzyme-linked immunosorbent assay (ELISA) using com-
mercially available anti-Protein A capture antibodies.
2.14. Dynamic light scattering (DLS)
Dynamic light scattering measurements were made with a
DynaPro Plate Reader II from Wyatt Technology (Santa Barbara, CA,
USA) with puriﬁed protein samples diluted to 5 g/L with 25 mM Tris,
150 mM NaCl, pH 7.5. Hydrodynamic radius was estimated using
Dynamics (v.7) software.
3. Results and discussion3.1. Linear pH gradient elution behavior
Fig. 1 shows results of linear pH gradient elution of mAb  2 on Z4,
Z(H18S)4, and Z(H18S, N28A)4 stationary phases. As is seen in the
T.M. Pabst et al. / J. Chromatogr. A 1362 (2014) 180–185 183
Table  3
Summary of linear pH gradient elution.
Molecule pH at elution peak maximum
Z4 Z(H18S)4 Z(H18S, N28A)4
mAb1 3.6 3.8 4.0
mAb2 3.7 4.2 4.5
mAb3 3.7 4.1 4.4
mAb4 3.7 4.0 4.2
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lmAb5 3.6 3.9 4.0
BsAb 4.0 4.2 4.6
Fc1 3.7 5.4 -
gure, Z(H18S, N28A)4 elutes at higher pH than Z(H18S)4, which in
urn elutes at higher pH than Z4. The elution proﬁle, as determined
y peak height and shape, on all three resins was similar. Moreover,
he peaks all appeared fairly symmetric, showing slight fronting
uring the early part of elution.
The pattern shown in Fig. 1 was consistent across all antibodies
ested in this work. Table 3 summarizes results of linear pH gradient
lution experiments. For a single resin, differences were observed
n pH at elution peak maximum for different molecules. However,
or a single molecule, the trend was always the same where Z(H18S,
28A)4 elutes at higher pH than Z(H18S)4 which elutes at higher
H than Z4. The Fc1 molecule showed the greatest difference in
lution pH among the different resins. A value was  not reported
or the Z(H18S, N28A)4 resin as the protein began to elute isocrat-
cally prior to the start of the gradient at pH 6.7. Moreover, the
c1 molecule showed much broader elution peaks on the Z(H18S,
28A)4 and Z(H18S)4 resins compared to the Z4 resins as shown
n Fig. 2. This behavior, the reason for which is unknown, was  not
bserved for any antibodies.
.2. Dynamic binding capacity
Results of DBC experiments for mAb  5 are shown in Fig. 3.
he proﬁles showed the characteristic sigmoidal shape expected
or breakthrough curves. DBC results for all molecules tested are
hown in Table 4. Unlike the trend observed for linear pH gradient
lution experiments, as summarized in Table 3, for DBC of antibod-
es the highest capacity was observed for the Z(H18S)4 resin, the
econd highest capacity was seen with Z(H18S, N28A)4, and the
owest capacity was seen for Z4. However, the difference was  in
ur view minor and given the trend in DBC is similar to what one
ould expect based on the ligand density measurements, it cannot
e concluded that the mutations alone result in higher DBC. This
ould occur, for example, through higher binding stoichiometry.
onetheless, the fact that the mutations did not result in an
ig. 2. Elution of Fc1 in a linear pH gradient from 6.7 to 2.7 on Protein A columns
oaded to 5 g/L. The pH gradient is shown as a dotted line.Fig. 3. Breakthrough curves for mAb  5 on Protein A resins.
apparent decrease in DBC compared to Z4 ligand, which is used in
a modern commercial Protein A resin, is a signiﬁcant ﬁnding.
While mAbs showed very similar capacities when comparing
ligands, the behavior of the Fc-fusion protein was markedly differ-
ent. For this molecule, the capacity of all three resins was  much
lower compared to the antibodies and the novel ligands showed
lower capacity than the Z4 ligand. Again, as was  the case for the gra-
dient elution experiments, the reason for the behavior is unknown.
Based on prior work in this area we can speculate on possible
causes. In their detailed work, Ghose, Hubbard and Cramer noted
that binding stoichiometry for a panel of antibodies and Fc fusion
proteins ranged from 2.4 to 3.1, showing not all available Pro-
tein A binding domains could be fully utilized [12]. This effect
was attributed to intra-ligand steric hindrance. In the same work,
it was  noted that inter and intra-ligand steric hindrance strongly
impacted Protein A stationary phase binding capacity. The dynamic
light scattering results shown in Table 2 demonstrate the Fc1
molecule has the smallest hydrodynamic radius of any of the pro-
teins used in this work. Thus, inter-ligand steric hindrance would
seem to be an unlikely cause. As a result, the most likely explana-
tion is that features of the Fc1 molecule must exist which result in
severe intra-ligand hindrance. The novel mutations appear to exac-
erbate this effect, leading to lower capacity than seen for Z4. As each
Fc-fusion protein is unique, this data cannot be seen as predictive
for the behavior of other fusion constructs.
These results demonstrate that higher elution pH can be
achieved without sacriﬁcing DBC through novel point mutations
to the Z domain. However, other important properties such as the
impact of ligand mutations on selectivity under conditions typically
encountered in modern bioprocessing remain to be addressed. The
sections below are devoted to these topics.
Table 4
Summary of dynamic binding capacities for antibodies and an Fc-fusion protein on
Protein A resins.
Molecule DBC10% (g/L resin)
Z4 Z(H18S)4 Z(H18S, N28A)4
mAb1 43.8 50.7 49.3
mAb2 39.0 44.5 43.9
mAb3 42.5 47.3 43.1
mAb4 41.2 47.4 46.8
mAb5 46.2 51.5 51.9
BsAb 48.3 52.9 49.8
Fc1  21.7 17.7 14.0
184 T.M. Pabst et al. / J. Chromatogr. A 1362 (2014) 180–185
Table  5
Summary of pH 4.0 stepwise elution experiments.
Molecule Yield (%)
Z4 Z(H18S)4 Z(H18S, N28A)4
mAb1 60.8 72.4 76.4
mAb2 71.2 95.4 97.9
mAb3 69.5 94.0 98.2
mAb4 62.6 85.6 90.8
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Table 6
Host cell protein clearance from clariﬁed cell broth.
HCP (ng/mg)
mAb1 mAb2 mAb5 Fc1
Load (CB) 34,305 398,406 30,769 66,445
Pool—pH 3.5 elution
Z4 497 1088 268 671
Z(H18S)4 559 323 216 522
Z(H18S, N28A)4 231 315 659 457
Pool—pH 4.0 elutionmAb5 48.2 80.1 88.5
BsAb 57.0 66.4 69.7
Fc1  11.1 89.1 93.1
.3. Stepwise elution behavior
Table 5 summarizes results of stepwise elution experiments at
H 4.0. In most cases, there is a marked increase in yield when com-
aring the Z(H18S)4 and Z(H18S, N28A)4 resins to the Z4 resin. This
bservation further corroborates the linear gradient elution data. It
lso demonstrates a beneﬁt can be obtained from the Z(H18S)4 and
(H18S, N28A)4 resins under conditions of high loading typically
ncountered in bioprocessing.
The difference in yield was most dramatic for the Fc fusion pro-
ein, where it increased from 11% on Z4 to 89% and 93% on the
(H18S)4 and Z(H18S, N28A)4 resins, respectively. For the antibod-
es the average yield increased 21% when comparing Z(H18S)4 to
4 and 25% when comparing Z(H18S, N28A)4 to Z4.
.4. Puriﬁcation of proteins from clariﬁed cell culture broth and
onspeciﬁc binding
Fig. 4 shows a representative chromatogram obtained for puriﬁ-
ation of the Fc1 molecule from clariﬁed cell culture broth (CB) on
he Z(H18S)4 resin with pH 4.0 elution. Puriﬁcation from CB on
oth the Z(H18S)4 and Z(H18S, N28A)4 was similar to that of Z4,
esulting in product elution peaks having volumes of less than 2CV.
Table 6 summarizes HCP clearance for three antibodies and the
c1 molecule. No trends were observed with respect to removal of
CP across the different resins and molecules tested. This result
s consistent with prior work suggesting HCP levels post Protein A
re largely dependent on interactions between the antibody and
he HCP, with little contribution due to interactions between the
esin and the HCP [29,30].
As an additional test for nonspeciﬁc binding, recombinant HSA
as loaded on each column to 30 g/L resin and the column was
ashed with 1 M NaCl, eluted, stripped, and sanitized as normal.
ig. 4. Representative chromatogram showing puriﬁcation of Fc1 clariﬁed cell cul-
ure broth on Z(H18S)4. The column was loaded to 10 g/L resin and eluted at pH
.0.Z(H18S)4 727 135 236 431
Z(H18S, N28A)4 372 95 176 352
No nonspeciﬁc binding was observed during the run as determined
by the chromatography workstation UV trace. In addition, a blank
run was  performed after the HSA run, no carry over was observed
based on the UV trace.
3.5. Impact of elution condition on a pH sensitive molecule
Table 7 summarizes results of monomer purity obtained in elu-
tion pools for puriﬁcation of Fc1 on the Z4, Z(H18S)4 and Z(H18S,
N28A)4 resins after a 24 h hold at room temperature without
neutralization. These conditions represent a realistic bioprocess
scenario, where product pools must frequently be held for planned
or unplanned reasons such as equipment malfunctions or process
deviations. For this molecule, the ability to elute at higher pH trans-
lated into 45% reduction in aggregate levels. The higher monomer
purity and reduced aggregate burden has obvious beneﬁts, as
separation of protein aggregates often represents a signiﬁcant chal-
lenge. Thus, the ability to achieve reduction in aggregate levels can
be expected to lead to higher manufacturing facility throughput
and lower cost of goods.
3.6. Resin lifetime and ligand stability
Protein A resin lifetime is considered critically important to the
success of modern bioprocessing. As part of this work, greater than
30 use cycles were performed on all three resins. Each cycle con-
sisted of protein loading, elution, low pH strip with 0.1 M acetic
acid, and sanitization with 0.1N NaOH. Although not done as part of
a formal resin lifetime study, and therefore conditions varied from
run to run, no deterioration in performance was observed over the
course of this study. Process performance and product quality after
30 cycles was  similar to that obtained for early cycles. Consistent
with what would be expected based on structural similarity, this
suggests the novel ligands are likely to have stability proﬁles similar
to the Z4 ligand used in MabSelect SuRe.
To further investigate ligand stability, levels of leached Protein
A ligand were measured by ELISA in the product pool for all three
resins operated under typical bind and elute conditions. As is shown
in Table 8, levels of leached Protein A ligand were low, less than
1 ppm in each case, and were similar for all three resins. This result
Table 7
HP-SEC analysis of Fc1 in Protein A elution pools after 24 h hold at room temperature.
Elution pool HP-SEC (% aggregate)
pH 3.5 elution
Z4 34.0
Z(H18S)4 33.2
Z(H18S, N28A)4 32.5
pH 4.0 elution
Z(H18S)4 18.0
Z(H18S, N28A)4 18.3
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Table  8
Summary of leached Protein A ligand in elution pools as measured by ELISA.
Molecule Leached Protein A (ng/mg mAb)
c
Z
u
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t
c
w
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t
p
n
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g
s
t
R
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[
[Z4 Z(H18S)4 Z(H18S, N28A)4
mAb1 0.56 0.33 0.33
onﬁrms that the stability of the novel ligands is comparable to the
4 ligand used in MabSelect SuRe, and thus acceptable for industrial
se.
. Conclusions
This work demonstrates novel Staphylococcal Protein A muta-
ions that result in milder elution pH for use in afﬁnity
hromatography. With one exception, this was accomplished
ithout sacriﬁcing dynamic binding capacity or other desirable
ttributes such as selectivity. This work highlights the great poten-
ial Protein A still holds for future advances. As has happened in the
ast, improvements to this important bioprocessing platform tech-
ology will help drive the next generation of protein therapeutics.
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